123 related articles for article (PubMed ID: 8474683)
1. Quinolinic acid lesion of the striatum induces impairment in spatial learning and motor performance in rats.
Block F; Kunkel M; Schwarz M
Neurosci Lett; 1993 Jan; 149(2):126-8. PubMed ID: 8474683
[TBL] [Abstract][Full Text] [Related]
2. Chronic administration of quinolinic acid in the rat striatum causes spatial learning deficits in a radial arm water maze task.
Shear DA; Dong J; Haik-Creguer KL; Bazzett TJ; Albin RL; Dunbar GL
Exp Neurol; 1998 Apr; 150(2):305-11. PubMed ID: 9527900
[TBL] [Abstract][Full Text] [Related]
3. Progressive behavioural changes in the spatial open-field in the quinolinic acid rat model of Huntington's disease.
Scattoni ML; Valanzano A; Popoli P; Pezzola A; Reggio R; Calamandrei G
Behav Brain Res; 2004 Jul; 152(2):375-83. PubMed ID: 15196806
[TBL] [Abstract][Full Text] [Related]
4. Comparison of intrastriatal injections of quinolinic acid and 3-nitropropionic acid for use in animal models of Huntington's disease.
Shear DA; Dong J; Gundy CD; Haik-Creguer KL; Dunbar GL
Prog Neuropsychopharmacol Biol Psychiatry; 1998 Oct; 22(7):1217-40. PubMed ID: 9829299
[TBL] [Abstract][Full Text] [Related]
5. Visual evoked potentials in the rat quinolinic acid model of Huntington's disease.
Schwarz M; Block F
Neurosci Lett; 1993 Apr; 152(1-2):81-3. PubMed ID: 8390629
[TBL] [Abstract][Full Text] [Related]
6. Abnormalities of somatosensory evoked potentials in the quinolinic acid model of Huntington's disease: evidence that basal ganglia modulate sensory cortical input.
Schwarz M; Block F; Töpper R; Sontag KH; Noth J
Ann Neurol; 1992 Sep; 32(3):358-64. PubMed ID: 1329611
[TBL] [Abstract][Full Text] [Related]
7. Adenosine A2A receptor blockade before striatal excitotoxic lesions prevents long term behavioural disturbances in the quinolinic rat model of Huntington's disease.
Scattoni ML; Valanzano A; Pezzola A; March ZD; Fusco FR; Popoli P; Calamandrei G
Behav Brain Res; 2007 Jan; 176(2):216-21. PubMed ID: 17123640
[TBL] [Abstract][Full Text] [Related]
8. Expression of GFAP in the striatum and its projection areas in response to striatal quinolinic acid lesion in rats.
Block F; Schwarz M
Neuroreport; 1994 Nov; 5(17):2237-40. PubMed ID: 7881035
[TBL] [Abstract][Full Text] [Related]
9. Improvement of mitochondrial function by paliperidone attenuates quinolinic acid-induced behavioural and neurochemical alterations in rats: implications in Huntington's disease.
Mishra J; Kumar A
Neurotox Res; 2014 Nov; 26(4):363-81. PubMed ID: 24752928
[TBL] [Abstract][Full Text] [Related]
10. Electrolytic lesion of globus pallidus ameliorates the behavioral and neurodegenerative effects of quinolinic acid lesion of the striatum: a potential novel treatment in a rat model of Huntington's disease.
Joel D; Ayalon L; Tarrasch R; Veenman L; Feldon J; Weiner I
Brain Res; 1998 Mar; 787(1):143-8. PubMed ID: 9518584
[TBL] [Abstract][Full Text] [Related]
11. 3-Hydroxykynurenine toxicity on the rat striatum in vivo.
Nakagami Y; Saito H; Katsuki H
Jpn J Pharmacol; 1996 Jun; 71(2):183-6. PubMed ID: 8835646
[TBL] [Abstract][Full Text] [Related]
12. Amelioration of behavioral deficits in a rat model of Huntington's disease by an excitotoxic lesion to the globus pallidus.
Ayalon L; Doron R; Weiner I; Joel D
Exp Neurol; 2004 Mar; 186(1):46-58. PubMed ID: 14980809
[TBL] [Abstract][Full Text] [Related]
13. Behavioral and anatomical effects of quinolinic acid in the striatum of the hemiparkinsonian rat.
Olds ME; Jacques DB; Kopyov O
Synapse; 2005 Jan; 55(1):26-36. PubMed ID: 15499610
[TBL] [Abstract][Full Text] [Related]
14. Neurogenesis in the striatum of the quinolinic acid lesion model of Huntington's disease.
Tattersfield AS; Croon RJ; Liu YW; Kells AP; Faull RL; Connor B
Neuroscience; 2004; 127(2):319-32. PubMed ID: 15262322
[TBL] [Abstract][Full Text] [Related]
15. Age-dependent differences in survival of striatal somatostatin-NPY-NADPH-diaphorase-containing interneurons versus striatal projection neurons after intrastriatal injection of quinolinic acid in rats.
Figueredo-Cardenas G; Chen Q; Reiner A
Exp Neurol; 1997 Aug; 146(2):444-57. PubMed ID: 9270055
[TBL] [Abstract][Full Text] [Related]
16. Quinolinic acid released from polymeric brain implants causes behavioral and neuroanatomical alterations in a rodent model of Huntington's disease.
Haik KL; Shear DA; Schroeder U; Sabel BA; Dunbar GL
Exp Neurol; 2000 Jun; 163(2):430-9. PubMed ID: 10833318
[TBL] [Abstract][Full Text] [Related]
17. Behavioral and electrophysiological correlates of the quinolinic acid rat model of Huntington's disease in rats.
Popoli P; Pèzzola A; Domenici MR; Sagratella S; Diana G; Caporali MG; Bronzetti E; Vega J; Scotti de Carolis A
Brain Res Bull; 1994; 35(4):329-35. PubMed ID: 7850482
[TBL] [Abstract][Full Text] [Related]
18. Relative survival of striatal projection neurons and interneurons after intrastriatal injection of quinolinic acid in rats.
Figueredo-Cardenas G; Anderson KD; Chen Q; Veenman CL; Reiner A
Exp Neurol; 1994 Sep; 129(1):37-56. PubMed ID: 7925841
[TBL] [Abstract][Full Text] [Related]
19. [Behavior characterization of a model of Huntington's disease in rats, induced by quinolinic acid].
Francis L; Cruz R; Antúnez I; Rosillo JC
Rev Neurol; 2000 Jun 1-15; 30(11):1016-21. PubMed ID: 10904945
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective effect of naringin, a flavone glycoside in quinolinic acid-induced neurotoxicity: Possible role of PPAR-γ, Bax/Bcl-2, and caspase-3.
Cui J; Wang G; Kandhare AD; Mukherjee-Kandhare AA; Bodhankar SL
Food Chem Toxicol; 2018 Nov; 121():95-108. PubMed ID: 30130594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
